Millicom International Cellular S.A. Common Stock vs GeneDx Holdings Corp — how do they compare? Millicom International Cellular S.A. Common Stock trades at $80.51 (market cap $13.49B), while GeneDx Holdings Corp trades at $68.61 (market cap $2.04B). The key difference: Millicom International Cellular S.A. Common Stock is far larger — about 6.6× GeneDx Holdings Corp's market cap, and Millicom International Cellular S.A. Common Stock pays a 3.73% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Millicom International Cellular S.A. Common Stock for 0 Days and GeneDx Holdings Corp for 20 Days on average.
| TIGO | WGS | |
|---|---|---|
Market Cap | $13.49B | $2.04B |
Volume | 1,314,537 | 962,082 |
Sector | Media | Health |
52-Week High | $104.31 | $167.51 |
52-Week Low | $45.81 | $34.51 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $24.53B | $2.08B |
Dividend Yield | 3.73% | — |
Signals from Pluang's Aura AI — not financial advice
TIGO trades at $79.54, down 0.92% on the day, with a neutral technical signal and key support at $79. The company reported strong 2025 results with $5.82B revenue and $1.32B net income, but 2026 earnings have missed expectations in two of the last three quarters. Recent news highlights its addition to Zacks' Strong Buy list and a consistent $0.75 quarterly dividend.
The stock offers a 12.9% upside to the consensus price target of $89.78, supported by solid profitability and cash flow, but faces risks from earnings volatility and high debt. Analyst sentiment is mixed with a Hold consensus, suggesting cautious optimism amid integration challenges from recent acquisitions.
GeneDx Holdings (WGS) trades at $64.96, up 1.79% today, showing mixed technical signals with a bearish moving average trend but bullish oscillators. Fundamentally, the company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows a net loss of -$106M. Recent news highlights product launches and CEO recognition, while analyst sentiment remains strongly positive with 91% buy ratings.
The outlook for WGS is cautiously optimistic with strong analyst support and operational improvements, but significant risks persist including negative profitability margins and high valuation multiples. The consensus price target of $81 suggests 25% upside potential, though investors should monitor cash flow trends and competitive pressures in the genomics diagnostics space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Millicom International Cellular S.A. operates telecommunications and digital services under the Tigo brand across Latin America, providing mobile, fiber broadband, and pay-TV services. The company also offers mobile financial services through its Tigo Money business.
Read more on TIGO →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →